Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AI/ML Innovations (CSE:AIML, OTCQB:AIMLF, FSE:42FB) announced a proposed non-brokered private placement of up to 40,000,000 units at $0.05 per unit, for potential gross proceeds of up to $2,000,000. Each unit consists of one common share and one common share purchase warrant.
Each whole warrant will be exercisable at $0.15 per share for 60 months from issuance, subject to anti-dilution provisions. The Offering is subject to closing conditions, including Canadian Securities Exchange approval. The company may pay cash finders’ fees and issue broker warrants of up to 7% of units, each exercisable at $0.15 for five years. The securities will not be registered under the U.S. Securities Act of 1933 and are not being offered in the United States.
AI/ML Innovations (OTCQB:AIMLF) announced that its wholly owned subsidiary NeuralCloud Solutions has achieved ISO 13485:2016 certification under the Medical Device Single Audit Program (MDSAP) for its quality management system. The certification by TÜV USA covers design, development, production, and distribution of ECG-focused Software as a Medical Device, including MaxYield™ and CardioYield™ platforms.
According to the company, this audited framework supports NeuralCloud’s regulatory, clinical, and commercialization plans for AI-driven cardiac signal analysis across multiple jurisdictions including Canada, the United States, Australia, Brazil, and Japan, while not itself constituting product clearance or marketing authorization.
AI/ML Innovations (OTCQB:AIMLF) completed a share-for-debt transaction with certain service providers. The company issued 3,560,334 common shares at a deemed price of C$0.05 per share to settle past services and outstanding indebtedness. A statutory hold period applies until November 3, 2026.
Insiders acquired 1,933,334 shares, making this a related party transaction under MI 61‑101. According to the company, exemptions from formal valuation and minority approval apply because the fair market value involved with related parties is below 25% of market capitalization.
AI/ML Innovations (OTCQB:AIMLF) announced that subsidiary NeuralCloud received U.S. Patent No. 12,622,625 B2 for machine learning ECG analysis, covering denoising, rhythm classification, labelling and report generation across wearable and clinical workflows.
The company also plans to settle debt by issuing 3,560,334 shares at C$0.05, including insider participation, subject to Canadian Securities Exchange approval.
AI/ML (CSE:AIML, OTCQB:AIMLF) announced that subsidiary NeuralCloud appointed Dale DuBois as Clinical Operations Lead and Nicholas DuBois as Vice President of Overread Operations.
The hires add over 50 years of cardiac monitoring, ECG overread, and regulatory-validation experience/b) as NeuralCloud advances its neural-network ECG signal-processing technology through development and regulatory review toward potential commercialization.
AI/ML Innovations (OTCQB:AIMLF) closed the second and final tranche of a non-brokered private placement of convertible debentures, raising an aggregate principal of $2,867,500. The new tranche totals $1,917,500.
Debentures convert at $0.05 per unit, carry 10% interest, mature on May 11, 2029, and include 36‑month warrants at $0.15. Final CSE approval is pending.
AI/ML Innovations (OTCQB:AIMLF) appointed Dr. Martin Stephen Green, a 45-year authority in electrocardiography and founding architect of Canadian cardiac electrophysiology, to its Medical Advisory Board effective April 27, 2026.
His expertise supports AIML's AI-driven ECG platform across clinical validation, regulation, and commercial deployment in major Canadian cardiac centres.
AI/ML Innovations (OTCQB:AIMLF, CSE:AIML) completed a share-for-debt issuance on April 24, 2026, issuing 17,118,420 common shares at a deemed price of Cdn$0.05 per share for total consideration of Cdn$855,921 to settle past services and outstanding indebtedness. Insiders acquired 11,848,000 Subject Shares, triggering a related party designation under MI 61-101, though the company relied on exemptions to avoid formal valuation and minority approval. The Subject Shares carry a statutory hold expiring August 25, 2026. The securities are not registered for sale in the United States.
AI/ML Innovations (OTCQB:AIMLF) completed a previously announced share-for-debt issuance on April 17, 2026, issuing 17,118,420 common shares at a deemed price of C$0.05 per share to settle past services and outstanding indebtedness.
Insiders acquired 11,848,000 of the Subject Shares, triggering a related‑party designation under MI 61-101; the company relied on specified exemptions and the Subject Shares carry a statutory hold until August 18, 2026.
AI/ML Innovations (OTCQB:AIMLF) said its subsidiary Neural Cloud signed a reseller agreement on March 25, 2026 with a European digital cardiac monitoring platform to integrate and resell MaxYield™ ECG signal‑processing technology.
The collaboration aims to expand device‑agnostic, cloud‑based remote ECG and HRV analytics for clinicians, enabling cleaner waveform data for downstream diagnostics and preventive cardiology applications.